chinese-cancer-treatment-company-aims-for-us-listing

Chinese cancer treatment company aims for US listing

Concord Medical Services aims to raise up to $138 million from an IPO and is expected to start trading on the NYSE late next week.

Concord Medical Services, the operator of China's largest network of cancer treatment centres, has started to accept orders for an initial public offering that aims to raise between $114 million and $138 million. The Beijing-based company is expected to start trading on the New York Stock Exchange towards the end of next week.

Concord will provide an opportunity for international investors to get exposure to a Chinese healthcare company that operates at the patient level. So far, investors have been able to invest in companies involved in pharmaceuticals or the provision of medical equipment, but not the actual treatment of patients. The last Chinese company in the healthcare sector to go public was Sinopharm, a...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222